1. Enz A, Floersheim P (1996) Cholinesterase inhibitors: an overview of their mechanisms of action. In: Giacobini E, Becker R (eds) Alzheimer’s disease: from molecular biology to therapy. Birkhäuser, Boston, pp 211–215
2. Enz A, Hofmann A, Gmelin G, Kelly PH (1989) Pharmacological properties of the preferentially centrally acting acetylcholinesterase inhibitor SD2 ENA 713. In: Kewitz H, Thomsen T, Bickel U (eds) Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Zuckschwerdt, München, pp 271–277
3. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowsky J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. In: Cuello AC (ed) Colinergic function and dysfunction. Elsevier, Amsterdam, pp 431–438 (Prog Brain Res 98)
4. Karczmar A (1978) Exploitable aspects of cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions. In: Jenden D, Hanin I (eds) Cholinergic mechanism and psychopharmacology. Plenum Press, New York, pp 679–708
5. Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FR (1993) Molecular and cellular biology of cholinesterases. Prog Neurobiol 41: 31–91 The molecular forms of Cholinesterase and acetylcholinesterase in vertebrates. Ann Rev Neurosci 5: 57–106